RVL Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, the company reported revenue was USD 49.721 million compared to USD 17.501 million a year ago. Net loss was USD 51.692 million compared to USD 64.920 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 1.23 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 1.23 a year ago. Basic loss per share was USD 0.58 compared to USD 0.96 a year ago. Diluted loss per share was USD 0.58 compared to USD 0.96 a year ago.